Gene therapy delivery of endostatin enhances the treatment efficacy of radiation

Radiotherapy and Oncology

Volumn 66, Issue 1, 2003, Pages 1-9

  Shi, Wenyin ^a   Teschendorf, Christian ^a,c   Muzyczka, Nicholas ^a   Siemann, Dietmar W ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Adeno associated virus; Anti angiogenic therapy; Colorectal neoplasms; Endostatin; Radiotherapy

Indexed keywords

ADENOVIRUS VECTOR; BETA ACTIN; ENDOSTATIN; RECOMBINANT PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; GENE CONTROL; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; MOLECULAR CLONING; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RADIATION RESPONSE; SUSTAINED DRUG RELEASE; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

EID: 12244252749     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00280-3     Document Type: Article

References (40)

1. Auerbach W., Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther. 63:1994;265-311.
2. Bertolini F., Fusetti L., Mancuso P., et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood. 96:2000;282-287.
3. Blezinger P., Wang J., Gondo M., et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 17:1999;343-348.
4. Bloch W., Huggel K., Sasaki T., et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. Fed Am Soc Exp Biol J. 14:2000;2373-2376.
5. Burke P.A., DeNardo S.J. Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol. 39:2001;155-171.
6. Chen C.T., Lin J., Li Q., et al. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther. 11:2000;1983-1996.
7. Chen Q.R., Kumar D., Stass S.A., Mixson A.J. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 59:1999;3308-3312.
8. Dhanabal M., Ramchandran R., Volk R., et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 59:1999;189-197.
9. Dhanabal M., Ramchandran R., Waterman M.J., et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 274:1999;11721-11726.
10. Dhanabal M., Volk R., Ramchandran R., Simons M., Sukhatme V.P. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun. 258:1999;345-352.
11. Feldman A.L., Restifo N.P., Alexander H.R., et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. 60:2000;1503-1506.
12. Fisher K.J., Jooss K., Alston J., et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 3:1997;306-312.
13. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31.
14. Ge Y., Powell S., Van Roey M., McArthur J.G. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood. 97:2001;3733-3737.
15. Grimm D., Kleinschmidt J.A. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum Gene Ther. 10:1999;2445-2450.
16. Hanna N.N., Seetharam S., Mauceri H.J., et al. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 6:2000;287-293.
17. Herbst R.S., Lee A.T., Tran H.T., Abbruzzese J.L. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep. 3:2001;131-140.
18. Herzog R.W., Hagstrom J.N., Kung S.H., et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA. 94:1997;5804-5809.
19. Joki T., Machluf M., Atala A., et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol. 19:2001;35-39.
20. Kessler P.D., Podsakoff G.M., Chen X., et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 93:1996;14082-14087.
21. Lalwani A., Walsh B., Reilly P., et al. Long-term in vivo cochlear transgene expression mediated by recombinant adeno-associated virus. Gene Ther. 5:1998;277-281.
22. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 61:2001;253-270.
23. Mitchell M., Jerebtsova M., Batshaw M.L., Newman K., Ye X. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Ther. 7:2000;1986-1992.
24. Murphy J.E., Zhou S., Giese K., Williams L.T., Escobedo J.A., Dwarki V.J. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci USA. 94:1997;13921-13926.
25. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 158:1992;97-129.
26. Nguyen J.T. Adeno-associated virus and other potential vectors for angiostatin and endostatin gene therapy. Adv Exp Med Biol. 465:2000;457-466.
27. Nguyen J.T., Wu P., Clouse M.E., Hlatky L., Terwilliger E.F. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 58:1998;5673-5677.
28. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
29. Papetti M., Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 282:2002;C947-C970.
30. Regulier E., Paul S., Marigliano M., et al. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther. 8:2001;45-54.
31. Risau W. Mechanism of angiogenesis. Nature. 386:1997;671-674.
32. Sauter B.V., Martinet O., Zhang W.J., Mandeli J., Woo S.L. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA. 97:2000;4802-4807.
33. Shi W., Siemann D.W. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer. 87:2002;119-126.
34. Shi W., Teschendorf C., Siemann D.W. Adeno-associated virus mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 9:(6):2002;513-521.
35. Sidky Y.A., Auerbach R. Lymphocyte-induced angiogenesis in tumor-bearing mice. Science. 192:1976;1237-1238.
36. Soh E.Y., Eigelberger M.S., Kim K.J., et al. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery. 128:2000;1059-1065.
37. Solorzano C.C., Baker C.H., Bruns C.J., et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm. 16:2001;359-370.
38. Szary J., Szala S. Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. Int J Cancer. 91:2001;835-839.
39. Xiao X., Li J., Samulski R.J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associate virus vector. J Virol. 70:1996;8098-8108.
40. Zolotukhin S., Byrne B.J., Mason E., et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:1999;973-985.